This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe

ONLINE REGISTRATION CLOSES IN:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
Delivered as a Hybrid Event, 7 - 9 June, 2022
Live In-Person Event: 7 - 9 June, Postillion Hotel AmsterdamDigital Experience: All Sessions Livestreamed 7 - 9 June

Nebojsa Janjic, PhD
Chief Science Officer at SomaLogic, Inc.

Profile

Nebojsa Janjic has served as Chief Science Officer at SomaLogic since 2009. Prior to joining SomaLogic, Dr. Janjic was a founder and CSO of Replidyne, Inc., a biotechnology company focusing on the development of novel small-molecule antibacterial agents, whose mission is continuing through a successor company, Crestone, Inc., where he currently serves as advisor and Chairman of the Board. Prior to Replidyne, he was among the initial group of scientists to join the original aptamer company, NeXagen, which became NeXstar Pharmacauticals.  As Senior Director of Drug Discovery at NeXstar, he was responsible for creating a pipeline of aptamer-based drug candidates for pre-clinical and clinical development. His contributions included the discovery and early development of Macugen, the first-in-class, FDA-approved treatment for macular degeneration targeting VEGF and named Innovative Pharmaceutical Product of the Year in 2005. Dr. Janjic is currently involved in developing a new generation of chemically-modified aptamers and identifying opportunities for their use in science and medicine including high-content proteomics, biomarker discovery, super-resolution microscopy, and therapeutics. Dr. Janjic received his bachelor's degree in molecular biology and Ph.D. in physical organic chemistry from the University of Washington in Seattle and completed his postdoctoral training at the Scripps Research Institute in La Jolla as a Cancer Research Institute Fellow.

Agenda Sessions

  • Aptamer Engineering with Features Borrowed from Antibodies

    10:45